Journey Medical (NASDAQ:DERM) Earns Buy Rating from HC Wainwright

Journey Medical (NASDAQ:DERM)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $13.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 184.46% from the company’s previous close. HC Wainwright also issued estimates for Journey Medical’s Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.17 EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $1.16 EPS, FY2028 earnings at $1.76 EPS, FY2029 earnings at $1.90 EPS and FY2030 earnings at $2.01 EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Journey Medical in a research note on Wednesday, January 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Journey Medical Price Performance

NASDAQ DERM opened at $4.57 on Thursday. The company has a market cap of $152.00 million, a price-to-earnings ratio of -9.72 and a beta of 0.81. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.42 and a quick ratio of 1.12. The stock’s fifty day moving average price is $7.93 and its 200 day moving average price is $7.78. Journey Medical has a 1 year low of $4.51 and a 1 year high of $9.56.

Journey Medical (NASDAQ:DERM) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The company had revenue of $16.08 million during the quarter, compared to analysts’ expectations of $18.86 million. Journey Medical had a negative return on equity of 51.42% and a negative net margin of 18.48%. As a group, equities research analysts forecast that Journey Medical will post -1.02 earnings per share for the current year.

Institutional Investors Weigh In On Journey Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DERM. Sheets Smith Investment Management acquired a new position in shares of Journey Medical in the 3rd quarter valued at about $946,000. Essex Investment Management Co. LLC grew its holdings in Journey Medical by 55.1% during the third quarter. Essex Investment Management Co. LLC now owns 354,021 shares of the company’s stock worth $2,521,000 after acquiring an additional 125,818 shares during the period. SJS Investment Consulting Inc. acquired a new stake in Journey Medical during the third quarter worth about $107,000. JPMorgan Chase & Co. purchased a new position in Journey Medical during the second quarter valued at approximately $41,000. Finally, Raymond James Financial Inc. purchased a new position in Journey Medical during the second quarter valued at approximately $36,000. 7.25% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Journey Medical

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Q4 EPS beat street expectations — Journey reported EPS of ($0.04) vs. consensus ($0.06), which investors often view as a sign management is managing costs and edging toward profitability. Earnings Press Release
• Positive Sentiment: Management highlighted robust prescription demand for Emrosi and outlined a path to EBITDA growth and expanded Emrosi coverage — messaging that supports a profitability story if execution continues. Seeking Alpha: Emrosi & EBITDA Growth
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $13 price target (large upside vs. current levels), and published multi‑year EPS ramps that imply meaningful recovery/profitability over 2026–2030 — a catalyst for momentum investors. HC Wainwright Buy, $13 PT
• Neutral Sentiment: Analyst estimates were revised slightly downward in some out years (FY2026–2029) even as the Buy rating and $13 target remain; this moderates upside timing but keeps a bullish thesis intact. TipRanks Coverage
• Negative Sentiment: Revenue missed estimates — $16.08M vs. consensus ~$18.86M — and the company still shows negative margins and negative ROE, underscoring execution risk on the revenue side. Zacks: Q4 Metrics vs Estimates
• Negative Sentiment: Shares are trading near 12‑month lows and below key short‑term moving averages amid above‑average volume, indicating selling pressure and short‑term technical weakness. MarketBeat: DERM Stock Page

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.